Beijing Kawin Technology Share-Holding Valuation

Is 688687 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688687 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 688687 (CN¥25.56) is trading below our estimate of fair value (CN¥73.99)

Significantly Below Fair Value: 688687 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688687?

Key metric: As 688687 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 688687. This is calculated by dividing 688687's market cap by their current earnings.
What is 688687's PE Ratio?
PE Ratio	31.9x
Earnings	CN¥134.34m
Market Cap	CN¥4.28b

688687 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.4x
Enterprise Value/EBITDA	16.5x
PEG Ratio	1.1x

Price to Earnings Ratio vs Peers

How does 688687's PE Ratio compare to its peers?

The above table shows the PE ratio for 688687 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	62.7x
301080 AcrobiosystemsLtd	47.3x	29.9%	CN¥5.1b
688293 Shanghai OPM Biosciences	126.9x	60.0%	CN¥4.8b
002880 Shenzhen Weiguang Biological Products	25.8x	13.8%	CN¥6.5b
603739 Qingdao Vland Biotech	51x	20.4%	CN¥3.4b
688687 Beijing Kawin Technology Share-Holding	31.9x	28.6%	CN¥4.3b

Price-To-Earnings vs Peers: 688687 is good value based on its Price-To-Earnings Ratio (31.9x) compared to the peer average (62.7x).

Price to Earnings Ratio vs Industry

How does 688687's PE Ratio compare vs other companies in the CN Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 688687 is good value based on its Price-To-Earnings Ratio (31.9x) compared to the CN Biotechs industry average (36x).

Price to Earnings Ratio vs Fair Ratio

What is 688687's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688687 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	31.9x
Fair PE Ratio	27.7x

Price-To-Earnings vs Fair Ratio: 688687 is expensive based on its Price-To-Earnings Ratio (31.9x) compared to the estimated Fair Price-To-Earnings Ratio (27.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 688687 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	CN¥25.56	CN¥37.75 +47.7%	12.0%	CN¥44.13	CN¥34.13	n/a	3
Nov ’25	CN¥27.22	CN¥37.75 +38.7%	12.0%	CN¥44.13	CN¥34.13	n/a	3
Oct ’25	CN¥28.21	CN¥35.56 +26.0%	16.0%	CN¥45.01	CN¥30.60	n/a	4
Sep ’25	CN¥20.76	CN¥35.56 +71.3%	16.0%	CN¥45.01	CN¥30.60	n/a	4
Aug ’25	CN¥23.45	CN¥36.48 +55.6%	19.9%	CN¥48.72	CN¥30.60	n/a	4
Jul ’25	CN¥25.56	CN¥36.98 +44.7%	22.5%	CN¥48.72	CN¥30.60	n/a	3
Jun ’25	CN¥27.29	CN¥39.66 +45.3%	22.9%	CN¥48.72	CN¥30.60	n/a	2
May ’25	CN¥29.94	CN¥39.66 +32.5%	22.9%	CN¥48.72	CN¥30.60	n/a	2

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Dong-E-E-JiaoLtd

CN¥36.7b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥57.18

-1.8%

13.3%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.20

-3.1%

-24.5%

Hunan Jiudian Pharmaceutical

CN¥11.8b

Researches, develops, produces, and sells pharmaceutical products in China and internationally.

300705

CN¥23.80

-1.8%

12.8%